Aurinia Pharmaceuticals
AUPH
115 hedge funds and large institutions have $992M invested in Aurinia Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 28 increasing their positions, 19 reducing their positions, and 8 closing their positions.
629% more capital invested
Capital invested by funds: $136M → $992M (+$856M)
550% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 8
127% more call options, than puts
Call options by funds: $89.1M | Put options by funds: $39.3M
60% more funds holding
Funds holding: 72 → 115 (+43)
47% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 19
17.96% more ownership
Funds ownership: 27.74% → 45.7% (+18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$63.6M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$37.4M |
| 3 |
HM
HealthCor Management
New York
|
+$36.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$32.9M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$15.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
-$17.7M |
| 2 |
O
OrbiMed
New York
|
-$10.9M |
| 3 |
Goldman Sachs
New York
|
-$9.5M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.96M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.79M |
AUPH Hedge Fund Activity: Q4 2019 in Review
115 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2019, worth a combined $992M — up 629% from $136M a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new AUPH positions and 8 closed out — a net gain of 44 holders — while 28 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $63.6M. The largest seller was Polar Capital, exiting entirely with an estimated $17.7M sold.
- 115 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2019, up from 72 in Q3 2019.
- Funds reported $992M of Aurinia Pharmaceuticals stock for Q4 2019, up 629% quarter-over-quarter.
- 52 funds opened new Aurinia Pharmaceuticals positions in Q4 2019 and 8 closed out, a net change of +44 holders.
- The largest Aurinia Pharmaceuticals buyer in Q4 2019 was Fidelity Investments, an estimated $63.6M added.
- The largest Aurinia Pharmaceuticals seller in Q4 2019 was Polar Capital, an estimated $17.7M sold.
Based on aggregated 13F filings for Q4 2019.